PMID- 37080090
OWN - NLM
STAT- MEDLINE
DCOM- 20230516
LR  - 20230516
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 162
DP  - 2023 Jun
TI  - Therapeutic effects of Pulsatilla koreana Nakai extract on ovalbumin-induced 
      allergic rhinitis by inhibition of Th2 cell activation and differentiation via 
      the IL-4/STAT6/GATA3 pathway.
PG  - 114730
LID - S0753-3322(23)00518-8 [pii]
LID - 10.1016/j.biopha.2023.114730 [doi]
AB  - Allergic rhinitis (AR), caused by immunoglobulin E (IgE)-mediated inflammation, 
      generally occurs in the upper respiratory tract. T helper type 2 (Th2) 
      cell-mediated cytokines, including interleukin (IL)-4, IL-5, and IL-13, are 
      important factors in AR pathogenesis. Despite various treatment options, the 
      difficulty in alleviating AR and pharmacological side effects necessitate 
      development of new therapies. The root of Pulsatilla koreana Nakai (P. koreana), 
      a pasque flower, has been used as a herbal medicine. However, its effects on AR 
      remain unclear; therefore, we aimed to explore this subject in the current study. 
      The therapeutic effects of P. koreana water extract (PKN) on the 
      pathophysiological functions of the nasal mucosa was examined in ovalbumin 
      (OVA)-induced AR mice. The effect of PKN on Th2 activation and differentiation 
      was evaluated using concanavalin A-induced splenocytes and differentiated Th2 
      cells from naive CD4(+) T cells. We also investigated the effect of changes in 
      JAK/STAT6/GATA3 signaling on IL-4-induced Th2 cells. In OVA-induced AR mice, PKN 
      administration alleviated allergic nasal symptoms and decreased the total number 
      of immune cells, lymphocytes, neutrophils, and eosinophils in nasal lavage fluid; 
      serum levels of OVA-specific IgE, histamine, and IL-13 were also significantly 
      reduced. PKN also ameliorated OVA-induced nasal mucosal tissue thickening by 
      inhibiting inflammation and goblet cell hyperplasia. PKN treatment significantly 
      inhibited Th2 activity and differentiation through the IL-4/STAT-6/GATA3 pathway 
      in Th2 cells. PKN is an effective AR treatment with the potential to improve 
      patients' daily lives by regulating the allergic inflammatory response induced by 
      Th2 cells.
CI  - Copyright (c) 2023 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Jung, Dong Ho
AU  - Jung DH
AD  - KM Convergence Research Division, Korea Institute of Oriental Medicine, 1672 
      Yuseongdae-ro, Yuseong-gu, Daejeon 34054, the Republic of Korea.
FAU - Lee, Ami
AU  - Lee A
AD  - KM Convergence Research Division, Korea Institute of Oriental Medicine, 1672 
      Yuseongdae-ro, Yuseong-gu, Daejeon 34054, the Republic of Korea.
FAU - Hwang, Youn-Hwan
AU  - Hwang YH
AD  - KM Convergence Research Division, Korea Institute of Oriental Medicine, 1672 
      Yuseongdae-ro, Yuseong-gu, Daejeon 34054, the Republic of Korea.
FAU - Jung, Myung-A
AU  - Jung MA
AD  - KM Convergence Research Division, Korea Institute of Oriental Medicine, 1672 
      Yuseongdae-ro, Yuseong-gu, Daejeon 34054, the Republic of Korea.
FAU - Pyun, Bo-Jeong
AU  - Pyun BJ
AD  - KM Convergence Research Division, Korea Institute of Oriental Medicine, 1672 
      Yuseongdae-ro, Yuseong-gu, Daejeon 34054, the Republic of Korea.
FAU - Lee, Joo Young
AU  - Lee JY
AD  - KM Convergence Research Division, Korea Institute of Oriental Medicine, 1672 
      Yuseongdae-ro, Yuseong-gu, Daejeon 34054, the Republic of Korea.
FAU - Kim, Taesoo
AU  - Kim T
AD  - KM Convergence Research Division, Korea Institute of Oriental Medicine, 1672 
      Yuseongdae-ro, Yuseong-gu, Daejeon 34054, the Republic of Korea.
FAU - Song, Kwang Hoon
AU  - Song KH
AD  - KM Convergence Research Division, Korea Institute of Oriental Medicine, 1672 
      Yuseongdae-ro, Yuseong-gu, Daejeon 34054, the Republic of Korea. Electronic 
      address: ksong@kiom.re.kr.
FAU - Ji, Kon-Young
AU  - Ji KY
AD  - KM Convergence Research Division, Korea Institute of Oriental Medicine, 1672 
      Yuseongdae-ro, Yuseong-gu, Daejeon 34054, the Republic of Korea; Center for 
      Companion Animal New Drug Development, Jeonbuk Branch, Korea Institute of 
      Toxicology, 30 Baekhak1-gil, Jeongeup-si 56212, the Republic of Korea. Electronic 
      address: jky8387@kiom.re.kr.
LA  - eng
PT  - Journal Article
DEP - 20230418
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Cytokines)
RN  - 0 (Gata3 protein, mouse)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 0 (Interleukin-13)
RN  - 207137-56-2 (Interleukin-4)
RN  - 9006-59-1 (Ovalbumin)
RN  - 0 (Stat6 protein, mouse)
RN  - 0 (STAT6 Transcription Factor)
RN  - 0 (Plant Extracts)
SB  - IM
MH  - Animals
MH  - Mice
MH  - Cell Differentiation
MH  - Cytokines/metabolism
MH  - Disease Models, Animal
MH  - Immunoglobulin E
MH  - Inflammation/drug therapy
MH  - Interleukin-13/metabolism
MH  - Interleukin-4/metabolism
MH  - Mice, Inbred BALB C
MH  - Nasal Mucosa/metabolism
MH  - Ovalbumin
MH  - *Pulsatilla/chemistry
MH  - *Rhinitis, Allergic/drug therapy
MH  - STAT6 Transcription Factor/metabolism
MH  - *Th2 Cells
MH  - Plant Extracts/therapeutic use
OTO - NOTNLM
OT  - Allergic rhinitis
OT  - IL-4/STAT6/GATA3 pathway
OT  - Pulsatilla koreana Nakai
OT  - Th2 activation
OT  - Th2 cytokine
OT  - Th2 differentiation
COIS- Declaration of Competing Interest The authors declare that there are no conflicts 
      of interest.
EDAT- 2023/04/21 00:42
MHDA- 2023/05/03 06:42
CRDT- 2023/04/20 18:06
PHST- 2023/02/16 00:00 [received]
PHST- 2023/04/09 00:00 [revised]
PHST- 2023/04/17 00:00 [accepted]
PHST- 2023/05/03 06:42 [medline]
PHST- 2023/04/21 00:42 [pubmed]
PHST- 2023/04/20 18:06 [entrez]
AID - S0753-3322(23)00518-8 [pii]
AID - 10.1016/j.biopha.2023.114730 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2023 Jun;162:114730. doi: 10.1016/j.biopha.2023.114730. Epub 
      2023 Apr 18.